The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

Abstract

The preclinical characterization of AMG 160 highlights its potent antitumor activity <i>in vitro</i> and <i>in vivo</i>, and its potential for use with known diagnostic or therapeutic agents in mCRPC. These data support the ongoing clinical evaluation of AMG 160 in patients with mCRPC.<i>See related commentary by Kamat et al., p. 2675</i>.